ATE356631T1 - Orale verabreichung von parathyroidhormon und calcitonin - Google Patents

Orale verabreichung von parathyroidhormon und calcitonin

Info

Publication number: ATE356631T1
Authority: AT; Austria
Prior art keywords: calcitonin; oral administration; parathyroid hormone; pth; effective amount
Prior art date: 2001-06-01

Application number

AT02750997T

Other languages

English (en)

Inventor

Joseph M Ault

Moise Azria

Simon David Bateman

James F Mcleod

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-01

Filing date

2002-05-31

Publication date

2007-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE356631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-31 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2007-04-15 Application granted granted Critical

2007-04-15 Publication of ATE356631T1 publication Critical patent/ATE356631T1/de

Links

108090000445 Parathyroid hormone Proteins 0.000 title abstract 6
102000055006 Calcitonin Human genes 0.000 title abstract 2
108060001064 Calcitonin Proteins 0.000 title abstract 2
102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title abstract 2
229960004015 calcitonin Drugs 0.000 title abstract 2
239000000199 parathyroid hormone Substances 0.000 title abstract 2
229960001319 parathyroid hormone Drugs 0.000 title abstract 2
102100036893 Parathyroid hormone Human genes 0.000 abstract 4
208000037147 Hypercalcaemia Diseases 0.000 abstract 1
206010029148 Nephrolithiasis Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000000148 hypercalcaemia Effects 0.000 abstract 1
208000030915 hypercalcemia disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT02750997T 2001-06-01 2002-05-31 Orale verabreichung von parathyroidhormon und calcitonin ATE356631T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29516901P	2001-06-01	2001-06-01

Publications (1)

Publication Number	Publication Date
ATE356631T1 true ATE356631T1 (de)	2007-04-15

Family

ID=23136525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02750997T ATE356631T1 (de)	2001-06-01	2002-05-31	Orale verabreichung von parathyroidhormon und calcitonin

Country Status (25)

Country	Link
US (2)	US20040186050A1 (de)
EP (1)	EP1397156B1 (de)
JP (2)	JP5073153B2 (de)
KR (3)	KR20090116836A (de)
CN (2)	CN101837120A (de)
AT (1)	ATE356631T1 (de)
AU (2)	AU2002344371B2 (de)
BR (1)	BRPI0209748B1 (de)
CA (1)	CA2446929C (de)
CO (1)	CO5540323A2 (de)
CZ (1)	CZ307145B6 (de)
DE (1)	DE60218842T2 (de)
EC (1)	ECSP034858A (de)
ES (1)	ES2282436T3 (de)
HU (1)	HU229613B1 (de)
IL (2)	IL158777A0 (de)
MX (1)	MXPA03011027A (de)
NO (1)	NO330093B1 (de)
NZ (1)	NZ529439A (de)
PL (1)	PL211976B1 (de)
PT (1)	PT1397156E (de)
RU (1)	RU2300392C2 (de)
SK (1)	SK287697B6 (de)
WO (1)	WO2002098453A2 (de)
ZA (1)	ZA200308625B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE356631T1 (de)	2001-06-01	2007-04-15	Novartis Pharma Gmbh	Orale verabreichung von parathyroidhormon und calcitonin
BRPI0211932B1 (pt)	2001-08-17	2016-12-06	Novartis Ag	composição farmacêutica na forma de dosagem sólida para liberação oral, e uso de sal dissódio de ácido n-(5-cloro-saliciloil)-8-aminocaprílico (5-cnac)
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
BRPI0616558B1 (pt)	2005-09-19	2021-09-08	Emisphere Technologies, Inc	Forma i do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, forma ii do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, solvato de etanol cristalino do sal dissódico do ácido n-(5-salicioloil)-8-aminocaprílico, forma iii do sal dissódico do ácido n-(5-clorossaliciloil)-5- aminocapróico, octahidrato do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, composição farmacêutica, processo para preparar a forma i do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, processo para preparar um solvato de monoetanol do sal dissódico do ácido n-(5-saliciloil)-8-(...)
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
BRPI0618469A2 (pt) *	2005-11-10	2011-08-30	Univ Michigan Tech	hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
JP2009515993A (ja) *	2005-11-17	2009-04-16	ノバルティスアクチエンゲゼルシャフト	医薬組成物
CN101952241B (zh)	2007-11-02	2014-06-11	艾米斯菲尔技术公司	治疗维生素b12缺乏的方法
JP5740689B2 (ja)	2008-08-18	2015-06-24	エンテラバイオエルティーディー．	タンパク質の経口投与用の方法および組成物
CN104857505A (zh) *	2008-08-18	2015-08-26	安特拉贝欧有限公司	用于口服给予蛋白质的方法和组合物
US8987201B2 (en)	2009-12-07	2015-03-24	Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en)	2011-03-31	2012-10-04	Zentiva, K.S.	Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104800564A (zh) *	2015-04-02	2015-07-29	中国人民解放军济南军区总医院	一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物
KR101796604B1 (ko) *	2016-08-30	2017-11-10	목포대학교 산학협력단	위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
WO2019098811A2 (ko)	2017-11-20	2019-05-23	주식회사 노브메타파마	Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
KR102115353B1 (ko) *	2019-05-17	2020-05-26	주식회사 노브메타파마	Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4692433A (en) *	1983-10-12	1987-09-08	The Regents Of The University Of California	Method and composition for regulating serum calcium levels of mammals
US5364840A (en) *	1989-12-05	1994-11-15	Vical, Inc.	Synthetic calcitonin peptides
US5118667A (en) *	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE69411154T2 (de) *	1993-02-22	1998-10-22	Alza Corp., Palo Alto, Calif.	Mittel zur oralen gabe von wirkstoffen
US5866536A (en) *	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5650386A (en)	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
US5723577A (en)	1995-07-13	1998-03-03	Biomeasure Inc.	Analogs of parathyroid hormone
US5955574A (en) *	1995-07-13	1999-09-21	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.	Analogs of parathyroid hormone
DK1093819T3 (da)	1997-02-07	2006-09-11	Emisphere Tech Inc	Forbindelse og præparat til tilförsel af aktive midler
SE9702401D0 (sv)	1997-06-19	1997-06-19	Astra Ab	Pharmaceutical use
DE19915272A1 (de) *	1999-04-03	2000-10-05	Vetter & Co Apotheker	Spritze für medizinische Zwecke
AU4216700A (en) *	1999-04-05	2000-10-23	Emisphere Technologies, Inc.	Disodium salts, monohydrates, and ethanol solvates
AU1189301A (en)	1999-10-29	2001-05-14	Eli Lilly And Company	A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) *	2000-12-06	2006-05-23	Novartis Ag	Pharmaceutical compositions for the oral delivery of pharmacologically active agents
ATE356631T1 (de)	2001-06-01	2007-04-15	Novartis Pharma Gmbh	Orale verabreichung von parathyroidhormon und calcitonin
BRPI0211932B1 (pt) *	2001-08-17	2016-12-06	Novartis Ag	composição farmacêutica na forma de dosagem sólida para liberação oral, e uso de sal dissódio de ácido n-(5-cloro-saliciloil)-8-aminocaprílico (5-cnac)
US7318925B2 (en) *	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone

2002
- 2002-05-31 AT AT02750997T patent/ATE356631T1/de active
- 2002-05-31 CA CA2446929A patent/CA2446929C/en not_active Expired - Fee Related
- 2002-05-31 MX MXPA03011027A patent/MXPA03011027A/es active IP Right Grant
- 2002-05-31 KR KR1020097022621A patent/KR20090116836A/ko not_active Application Discontinuation
- 2002-05-31 KR KR10-2003-7015524A patent/KR20040007617A/ko not_active Application Discontinuation
- 2002-05-31 WO PCT/EP2002/006017 patent/WO2002098453A2/en active Application Filing
- 2002-05-31 CN CN200910258008A patent/CN101837120A/zh active Pending
- 2002-05-31 BR BRPI0209748A patent/BRPI0209748B1/pt not_active IP Right Cessation
- 2002-05-31 US US10/478,631 patent/US20040186050A1/en not_active Abandoned
- 2002-05-31 HU HU0400120A patent/HU229613B1/hu not_active IP Right Cessation
- 2002-05-31 CZ CZ2003-3232A patent/CZ307145B6/cs not_active IP Right Cessation
- 2002-05-31 DE DE60218842T patent/DE60218842T2/de not_active Expired - Lifetime
- 2002-05-31 CN CNA028111613A patent/CN1512892A/zh active Pending
- 2002-05-31 PL PL364089A patent/PL211976B1/pl unknown
- 2002-05-31 RU RU2003136733/15A patent/RU2300392C2/ru not_active IP Right Cessation
- 2002-05-31 EP EP02750997A patent/EP1397156B1/de not_active Expired - Lifetime
- 2002-05-31 JP JP2003501491A patent/JP5073153B2/ja not_active Expired - Fee Related
- 2002-05-31 SK SK1475-2003A patent/SK287697B6/sk not_active IP Right Cessation
- 2002-05-31 NZ NZ529439A patent/NZ529439A/en not_active IP Right Cessation
- 2002-05-31 IL IL15877702A patent/IL158777A0/xx unknown
- 2002-05-31 AU AU2002344371A patent/AU2002344371B2/en not_active Ceased
- 2002-05-31 PT PT02750997T patent/PT1397156E/pt unknown
- 2002-05-31 ES ES02750997T patent/ES2282436T3/es not_active Expired - Lifetime
- 2002-05-31 KR KR1020127010903A patent/KR101320817B1/ko not_active IP Right Cessation
2003
- 2003-11-05 ZA ZA200308625A patent/ZA200308625B/xx unknown
- 2003-11-06 IL IL158777A patent/IL158777A/en not_active IP Right Cessation
- 2003-11-18 NO NO20035133A patent/NO330093B1/no not_active IP Right Cessation
- 2003-11-21 EC EC2003004858A patent/ECSP034858A/es unknown
- 2003-12-19 CO CO03111065A patent/CO5540323A2/es not_active Application Discontinuation
2006
- 2006-09-29 AU AU2006225157A patent/AU2006225157B2/en not_active Ceased
2008
- 2008-01-28 US US12/020,700 patent/US8153587B2/en not_active Expired - Fee Related
2010
- 2010-04-22 JP JP2010098631A patent/JP2010189423A/ja active Pending

Also Published As

Publication number	Publication date
NZ529439A (en)	2005-11-25
NO20035133D0 (no)	2003-11-18
MXPA03011027A (es)	2004-03-19
SK14752003A3 (sk)	2004-06-08
WO2002098453A2 (en)	2002-12-12
WO2002098453A3 (en)	2003-07-31
HU229613B1 (en)	2014-03-28
PL364089A1 (en)	2004-12-13
AU2006225157A1 (en)	2006-10-19
EP1397156A2 (de)	2004-03-17
JP2005500277A (ja)	2005-01-06
RU2300392C2 (ru)	2007-06-10
NO20035133L (no)	2003-11-18
HUP0400120A2 (hu)	2005-04-28
PT1397156E (pt)	2007-05-31
US8153587B2 (en)	2012-04-10
ZA200308625B (en)	2004-07-13
EP1397156B1 (de)	2007-03-14
KR20040007617A (ko)	2004-01-24
CO5540323A2 (es)	2005-07-29
US20080119411A1 (en)	2008-05-22
CA2446929A1 (en)	2002-12-12
CA2446929C (en)	2013-04-09
NO330093B1 (no)	2011-02-14
RU2003136733A (ru)	2005-05-20
HUP0400120A3 (en)	2012-09-28
IL158777A (en)	2012-06-28
PL211976B1 (pl)	2012-07-31
US20040186050A1 (en)	2004-09-23
JP2010189423A (ja)	2010-09-02
AU2006225157B2 (en)	2009-04-23
CZ20033232A3 (cs)	2004-06-16
CN1512892A (zh)	2004-07-14
SK287697B6 (sk)	2011-06-06
DE60218842T2 (de)	2007-12-20
IL158777A0 (en)	2004-05-12
KR20120065429A (ko)	2012-06-20
BRPI0209748B1 (pt)	2015-11-24
ECSP034858A (es)	2004-01-28
KR101320817B1 (ko)	2013-10-21
CN101837120A (zh)	2010-09-22
CZ307145B6 (cs)	2018-02-07
DE60218842D1 (de)	2007-04-26
KR20090116836A (ko)	2009-11-11
ES2282436T3 (es)	2007-10-16
JP5073153B2 (ja)	2012-11-14
AU2002344371B2 (en)	2006-06-29
BR0209748A (pt)	2004-07-27

Publication	Publication Date	Title
DE60218842D1 (de)	2007-04-26	Orale verabreichung von parathyroidhormon und calcitonin
AR033639A1 (es)	2004-01-07	Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
CY1109661T1 (el)	2014-08-13	5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
ATE302616T1 (de)	2005-09-15	Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
SE0202857D0 (sv)	2002-09-27	Method and compositions for preventing hormone induced adverse effects
DE69934831D1 (de)	2007-02-22	MULTIPLEXES, FüR DIE ORALE VERBABREICHUNG GEEIGNETES MEDIKAMENTENABGABESYSTEM
DK1267832T3 (da)	2004-08-30	Selvemulgerende lægemiddelafgivelsessystem, hvor fedtstoffet er valgfrit
GT199800177A (es)	2000-05-02	Combinacion eficaz para el tratamiento de la impotencia .
DE60019334D1 (de)	2005-05-12	Antivirale arznei
NO20026055L (no)	2003-02-24	Farmasöytiske komponenter innbefattende humant paratyreoideahormon og farmasöytiske sammenstninger for nasal administrering inneholdendekomponentene
ATE353224T1 (de)	2007-02-15	Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
AU2001267887A1 (en)	2002-04-11	Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
CA2385755A1 (en)	2001-04-05	Prevention of colorectal cancer
WO2001066102A3 (en)	2001-12-20	Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
FR2839450B1 (fr)	2006-04-07	Preparation medicamenteuse notamment pour le traitement des hernies discales
MD1473F2 (en)	2000-05-31	Antiherpetic remedy
AR023398A1 (es)	2002-09-04	Terapia para melanomas
ECSP003419A (es)	2000-11-24	Terapia para melanomas

Legal Events

Date	Code	Title	Description
2007-08-15	UEP	Publication of translation of european patent specification	Ref document number: 1397156 Country of ref document: EP

Date

Code

Title

Description

2007-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1397156

Country of ref document: EP